Geranylgeranylacetone, a non-toxic inducer of heat shock protein, induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis

Modern Rheumatology

Volumn 19, Issue 4, 2009, Pages 379-383

  Nanke, Yuki ^a   Kawamoto, Manabu ^a   Yago, Toru ^a   Chiba, Junji ^b   Yamanaka, Hisashi ^a   Kotake, Shigeru ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Geranylgeranylation; Rheumatoid arthritis; Statin; Synovitis

Indexed keywords

FLUINDOSTATIN; TEPRENONE; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CELL COUNT; CELL DEATH; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STAINING; SYNOVIOCYTE;

ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; CELL DEATH; CELLS, CULTURED; DITERPENES; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; FIBROBLASTS; HUMANS; INDOLES; SYNOVIAL MEMBRANE; TRYPAN BLUE;

EID: 68549125086     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0183-z     Document Type: Article

References (50)

1. Nanke Y, Kotake S, Akama H, Kamatani N. Alkaline phosphatase in rheumatoid arthritis patients: Possible contribution of bone-type ALP to the raised activities of ALP in rheumatoid arthritis patients. Clin Rheumatol. 2002;21:198-202.
2. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345-52.
3. Kotake S, Nanke Y, Mogi M, Kawamoto M, Furuya T, Yago T, et al. IFN-7gamma;-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol. 2005;35:3353-63.
4. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12-23.
5. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-9.
6. Grasser WA, Baumann AP, Petras SF, Harwood HJ Jr, Devalaraja R, Renkiewicz R, et al. Regulation of osteoclast differentiation by statins. J Musculoskelet Neuronal Interact. 2003;3:53-62.
7. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des. 2001;7:715-36.
8. Connor AM, Berger S, Narendran A, Keystone EC. Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts. Arthritis Res Ther. 2006;8:R94.
9. van Beek E, Lowik C, Karperien M, Papapoulos S. Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: The role of the retinoic acid receptor. Bone. 2006;38:167-71.
10. Sakoda K, Yamamoto M, Negishi Y, Liao JK, Nodo K, Izumi Y. Anti-inflammatory effects of simvastatin on human oral cells. Inflamm Regen. 2007;27(2):107-11.
11. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation. Arthritis Rheum. 2006;54:579-86.
12. Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T. Antiulcer effect of geranylgeranylacetone, a new acyclic polyisoprenoid on experimentally induced gastric and duodenal ulcers in rats. Arzneimittelforschung. 1981;31:799-804.
13. Terano A, Hiraishi H, Ota S, Sugimoto T. Geranylgeranylacetone, a novel anti-ulcer drug, stimulates mucus synthesis and secretion in rat gastric cultures cells. Digestion. 1986;33:206-10.
14. Nanke Y, Kotake S, Ninomiya T, Furuya T, Ozawa H, Kamatani N. Geranylgeranylacetone inhibits formation and function of human osteoclasts and prevents bone loss in tail-suspended rats and ovariectomized rats. Calcif Tissue Int. 2005;77:376-85.
15. Nanke Y, Kotake S, Kamatani N. The role of gernylgernylacetone in formation and function of osteoclasts. Osteoporos Jpn. 2004;12(2):69-72.
16. Nanke Y, Kotake S, Kamatani N. The role of vitamin K 2 and gernylgernylacetone in formation and function of osteoclast. Inflamm Regen. 2004;24:173-7.
17. Nanke Y, Kotake S, Kamatani N. Geranylgeranylacetone, and antiulcer drug, potently inhibits formation and function of human osteoclasts in vitro and bone loss in ovariectomized rats. Nippon Rinsho. 2004;63:575-9.
18. Yanaka A, Zhang S, Sato D, Tauchi M, Suzuki H, Shibahara T, et al. Geranylgeranylacetone protects the human gastric mucosa from dic induced injury via induction of heat shock protein 70. Digestion. 2007;75:148-55.
19. Tetsuya H, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology. 1999;111:345-57.
20. Takano T, Tsutsumi S, Tomisato W, Hoshino T, Tsuchiya T. Geranylgeranylacetone protects guinea pig gastric mucosal cells from gastric stressor-induced apoptosis. Dig Dis Sci. 2002;47:1546-53.
21. Hirakawa T, Rokutan K, Nikawa T, Kishi K. Geranylgeranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology. 1996;111:345-7.
22. Shinohara T, Takahashi N, Kohno H, Yamanaka K, Ooie T, Wakisaka O, et al. Mitochondria are targets for geranylgeranylacetone-induced cardio against ischemia-reperfusion in the rat heart. Am J Physiol Heart Circ Physiol. 2007;293:H1892-9.
23. Yamanaka K, Takahashi N, Ooie T, Kaneda K, Yoshimatsu H. Role of protein kinase C in geranylgernylacetone-induced expression of heat-shock protein 72 and cardioprotection in the rat heart. J Mol Cell Cardiol. 2003;35:785-94.
24. Suzuki S, Maruyama S, Sato W, Morita Y, Sato F, Miki Y, et al. Geranylgeranylacetone ameliorates ischemic acute renal failure via induction of Hsp 70. Kidney Int. 2005;67:2210-20.
25. Ichikawa T, Nakao K, Nakata K, Hamasaki K, Takeda Y, Kajiya Y, et al. Geranylgeranylacetone induces antiviral gene expression in human hepatoma cells. Biochem Biophys Res Commun. 2001;280:933-9.
26. Fudaba Y, Tashiro H, Ohdan H, Miyata Y, Shibata S, Shintaku S, et al. Efficacy of HSP 72 induction in rat liver by orally administrated geranylgernylacetone. Transpl Int. 2000;13:S278-81.
27. Kitamei H, Kitaichi N, Yoshida K, Nakai A, Fujimoto M, Kitamura M, et al. Association of heat shock protein 70 induction and the amelioration experimental autoimmune uveoritinitis in mice. Immunobiology. 2007;212:11-8.
28. Ooie T, Takahashi N, Saikawa T, Nawata T, Arikawa M, Yamanaka K, et al. Single oral dose of geranylgeranylacetone induces hear-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation. 2001;104:1837-43.
29. Harada C, Nakamura K, Guo X, Kitaichi N, Mitamura Y, Yoshida K, et al. Neuroprotective effect of geranylgeranylacetone againt ischemia-in retinal injury. Mol Vis. 2007;13:1601-7.
30. Nishida K, Ohta Y, Ishiguro I. Teprenone, an anti-ulcer agent, increases gastric mucosal mucus level via nitric oxide in rats. Jpn J Pharmacol. 1998;78(4):519-22.
31. Fujiki M, Hikawa T, Abe T, Uchida S, Morishige M, Sugita K, et al. Role of protein kinase C in neuroprotective effect of geranylgeranylacetone, a noninvasive inducing agent of heat shock protein, on delayed neuronal death caused by transient ischemia in rats. J Neurotrauma. 2006;23:1164-78.
32. Endo S, Hiramatsu N, Hayakawa K, Okamura M, Kasai A, Tagawa Y, et al. Geranylgeranylacetone, an inducer of HSP79, elicits unfolded prot response and coordinates cellular fate independently of HSP70. Mol Pharmacol. 2007;72:1337-48.
33. Uchida S, Fujiki M, Nagai Y, Abe T, Kobayashi H. Geranylgeranylacetone, a noninvasive heat shock protein inducer, in protein kinase C and leads to neuroprotection against cerebral infarction in rats. Neurosci Lett. 2006;396:220-4.
34. Rokutan K, Teshima S, Kawai T, Kawahara T, Kusumoro K, Mizushima T, et al. Geranylgeranylacetone stimulates mucin synthesis in cultured guinea pig gastric pit cells by inducing a neuronal nitric oxide syntheses. J Gastroenterol. 2000;35:673-81.
35. Brundel BJ, Shiroshita-Takeshita A, Qi X, Yeh YH, Chartier D, van Gelder IC, et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res. 2006;99:1394-402.
36. Yamamoto K, Sarukawa M, Ito T, Aoki H, Ichida M, Shimada K. An anti-ulcer drug, geranylgeranylacetone, suppresses inducible nitrogen syntheses in cultured vascular smooth muscle cells. J Hypertens. 2005;10:1847-53.
37. Hirota K, Nakamura H, Arai T, Ishii H, Bai J, Itoh T, et al. Geranylgeranylacetone enhances expression of thioredoxin and supresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Commun. 2000;275:825-30.
38. Sone M, Hayashi H, Yamamoto H, Hashino T, Mizushima T, Nakashima T. Up regulation of HSP by geranylgeranylacetone protects the cochlear wall from endotoxin-induced inflammation. Hear Res. 2005;204:140-6.
39. Yenari MA, Liu J, Zheng Z, Vexler ZS, Lee JE, Giffard RG. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann N Y Acad. 2005;1053:74-83.
40. Hashimoto K, Morishige K, Sawada K, Ogata S, Tahara M, Shimizu S, et al. Geranylgeranylacetone inhibits ovarian cancer progression in vitro. Biochem Biophys Res Commun. 2007;356:72-7.
41. Nishida T, Yabe Y, Fu HY, Hayashi Y, Asahi K, Eguchi H, et al. Geranylgeranylacetone induces cyclooxygenase-2 expression in culture gastric epithelial cells through NF-kappaB. Dig Dis Sci. 2007;8:1890-6.
42. Wojcik C, Napoli N. Ubiquitin-proteasome system and proteasome inhibition: New strategies in stroke therapy. Stroke. 2004;35:1506-18.
43. Okada S, Yabuki M, Kanno T, Hamazaki K, Yoshioka T, Horton AA, et al. Geranylgeranylacetone induces apoptosis in HL-60. Cell Struct Funct. 1999;24:161-8.
44. Kinderlerer AR, Steinberg R, Johns M, Harten SK, Lidington EA, Haskard DO, et al. Statin-induced expression of CD59 on vascular endothelium in hypoxia: A potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R130.
45. Kinderlerer AR, Steinberg R, Johns M, Harten SK, Lidington EA, Haskard DO, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524-30.
46. Kanda H, Hamasaki K, Kubo K, Tateishi S, Yonezumi A, Kanda Y, et al. Anti-inflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2024-5.
47. Jansen TL. Atorvastatine for chronic synovitis due to massive intra-articular cholesterol monohydrate deposition in long-standing rheumatoid arthritis. Rheumatology. 2006;45:1577-8.
48. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): Double-blind, randomized placebo-controlled trial. Lancet. 2006;363:2015-21.
49. Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y, et al. RhoA-medicated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: Inhibitory effect of simvastatin. Arthris Rheum. 2006;54:3441-51.
50. Goto M, Sasano M, Yamanaka H, Miyasaka N, Kamatani N, Inoue K, et al. Spontaneous production of an interleukin-1-like factor by cloned rheumatoid synovial cells in long-term culture. J Clin Invest. 1987;80:786-96.